Inovio Pharma (INO) Misses Q4 EPS by 14c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
INOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
March 12, 2020 4:05 PM EDTPLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ --Â INOVIO Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases, today reported financial results for the fourth quarter and year ended December 31, 2019. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.
INOVIO Highlights
VGX-3100: Cervical, vulvar, and anal HSIL
REVEAL 2 Phase 3 clinical trial... More
